1. Home
  2. ACRV vs XNET Comparison

ACRV vs XNET Comparison

Compare ACRV & XNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRV
  • XNET
  • Stock Information
  • Founded
  • ACRV 2018
  • XNET 2003
  • Country
  • ACRV United States
  • XNET China
  • Employees
  • ACRV N/A
  • XNET N/A
  • Industry
  • ACRV Medicinal Chemicals and Botanical Products
  • XNET Computer Software: Prepackaged Software
  • Sector
  • ACRV Health Care
  • XNET Technology
  • Exchange
  • ACRV Nasdaq
  • XNET Nasdaq
  • Market Cap
  • ACRV 189.0M
  • XNET 206.0M
  • IPO Year
  • ACRV 2022
  • XNET 2014
  • Fundamental
  • Price
  • ACRV $5.54
  • XNET $3.13
  • Analyst Decision
  • ACRV Strong Buy
  • XNET
  • Analyst Count
  • ACRV 6
  • XNET 0
  • Target Price
  • ACRV $22.40
  • XNET N/A
  • AVG Volume (30 Days)
  • ACRV 69.3K
  • XNET 346.0K
  • Earning Date
  • ACRV 03-27-2025
  • XNET 03-13-2025
  • Dividend Yield
  • ACRV N/A
  • XNET N/A
  • EPS Growth
  • ACRV N/A
  • XNET 146.84
  • EPS
  • ACRV N/A
  • XNET 0.23
  • Revenue
  • ACRV N/A
  • XNET $359,611,000.00
  • Revenue This Year
  • ACRV N/A
  • XNET N/A
  • Revenue Next Year
  • ACRV N/A
  • XNET N/A
  • P/E Ratio
  • ACRV N/A
  • XNET $13.83
  • Revenue Growth
  • ACRV N/A
  • XNET 99.13
  • 52 Week Low
  • ACRV $3.83
  • XNET $1.45
  • 52 Week High
  • ACRV $11.90
  • XNET $3.75
  • Technical
  • Relative Strength Index (RSI)
  • ACRV 47.59
  • XNET 60.15
  • Support Level
  • ACRV $5.00
  • XNET $2.88
  • Resistance Level
  • ACRV $6.08
  • XNET $3.75
  • Average True Range (ATR)
  • ACRV 0.64
  • XNET 0.29
  • MACD
  • ACRV 0.01
  • XNET 0.02
  • Stochastic Oscillator
  • ACRV 25.68
  • XNET 56.34

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

Share on Social Networks: